A Novel Antihepatitis Drug, Bicyclol, Prevents Liver Carcinogenesis in Diethylnitrosamine-Initiated and Phenobarbital-Promoted Mice Tumor Model

<table>Body weight profile in the control and experimental groups. Average values with standard deviations are shown. <svg height="10.8125" id="M9" style="vertical-align:-0.10033pt" version="1.1" viewbox="0 0 42.912498 10.8125" width="42.912498" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,10.8125)">
<g transform="translate(72,-63.35)">
<text transform="matrix(1,0,0,-1,-71.95,63.5)">
<tspan style="font-size: 12.50px; " x="0" y="0">𝑛</tspan>
<tspan style="font-size: 12.50px; " x="9.6773224" y="0">=</tspan>
<tspan style="font-size: 12.50px; " x="21.71771" y="0">1</tspan>
<tspan style="font-size: 12.50px; " x="27.969212" y="0">4</tspan>
</text>
</g>
</g>
</svg>-15.</table>

BioMed Research International

fig3

Figure 3

Figure 3: A Novel Antihepatitis Drug, Bicyclol, Prevents Liver Carcinogenesis in Diethylnitrosamine-Initiated and Phenobarbital-Promoted Mice Tumor Model 

Figure 3 | A Novel Antihepatitis Drug, Bicyclol, Prevents Liver Carcinogenesis in Diethylnitrosamine-Initiated and Phenobarbital-Promoted Mice Tumor Model 